Boston Scientific Shares Under Pressure as Truist Cuts Target on Watchman Slowdown

Key Facts

1Truist Securities lowered its price target for Boston Scientific from $85 to $64.

2The reduction is attributed to a slowdown in U.S. growth trends for the company’s Watchman device.

3Analysts noted declining management forecasting credibility and increasing investor fatigue.

Amid rising challenges in the high-growth medical device sector, Truist Securities significantly lowered its price target for Boston Scientific from $85 to $64. This downward adjustment is primarily attributed to a slowdown in U.S. growth trends for the company’s Watchman device, a critical product used for stroke risk reduction. Analysts further noted a decline in the credibility of management’s forecasting and an increasing sense of investor fatigue regarding future financial performance.

This target cut comes as competition in the cardiology space intensifies, with peer Abbott Laboratories (ABT) recently reporting a 10.8% growth in medical device sales in its latest quarterly filing. In comparison, the slowdown in Watchman sales raises concerns about Boston Scientific's market share, especially as the device has been a primary revenue driver in recent years. Per market data, the valuation premium BSX holds over its peers may face compression if momentum in core products continues to stall.

Traders should monitor technical support levels closely following this revision. Looking ahead to the economic calendar, the market will focus on the Fed Kashkari speech on May 29, 2026, which could impact sentiment for growth stocks within the healthcare sector. Upcoming U.S. inflation data will also be pivotal in determining financing costs for med-tech firms that rely on hospital capital expenditure cycles.